Nanocis (Rhenium Sulfide)

Rhenium sulfide, the active ingredient in Nanocis, is an investigational compound presented as an unspecified strength oral and subcutaneous formulation for oral and subcutaneous use. It is being evaluated for potential therapeutic applications in specialized patient populations.

GNH USA supplies Nanocis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Nanocis is currently under investigation for its potential activity in several therapeutic areas.

- Oncology research: exploratory studies assessing anti‑tumor effects in preclinical models. - Rare metabolic disorders: early‑phase trials evaluating enzyme modulation. - Immunomodulation: investigations into immune response regulation.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Headache: transient cranial discomfort. - Injection site pain: localized soreness after subcutaneous administration. - Fatigue: general tiredness or reduced energy. - Rash: mild skin irritation. - Dizziness: temporary sense of light‑headedness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Hepatic injury: signs of liver dysfunction such as jaundice. - Neutropenia: marked reduction in neutrophil count. - Thrombocytopenia: low platelet levels increasing bleeding risk. - Severe hypersensitivity: extensive rash, swelling, or organ involvement. - Organ failure: rare multi‑system compromise.

Nanocis should be used only under qualified medical supervision, with attention to patient-specific factors.

- Medical supervision: administer only under a prescriber's direction. - Monitoring labs: regularly assess liver and blood counts. - Pregnancy: avoid use unless benefits outweigh potential risks. - Breastfeeding: discontinue if nursing due to unknown excretion. - Concomitant immunosuppression: evaluate risk of enhanced immunosuppression. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Potential drug interactions have not been fully characterized; caution is advised when co‑administering other agents.

Major Interactions (Avoid): - Potent immunosuppressants: may amplify immunosuppressive effects. - Hepatotoxic drugs: increased risk of liver injury. - Anticoagulants: potential for heightened bleeding.

Moderate Interactions (Monitor Closely): - CYP450 substrates: possible alteration of metabolic clearance. - Live vaccines: may affect immune response efficacy.